An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Camurus AB
- 電話番号:+46 46 286 57 30
- メール:medicalinfo@camurus.com
研究場所
-
-
-
Leeds、イギリス、LS9 7TF
- まだ募集していません
- St James's University Hospital - Leeds Teaching Hospitals NHS Trust
-
-
-
-
-
Aachen、ドイツ、52074
- 募集
- Universitaetsklinikum Aachen
-
Leipzig、ドイツ、04103
- 募集
- Universitaetsklinikum Leipzig
-
Magdeburg、ドイツ、39110
- 募集
- Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
-
München、ドイツ、81667
- まだ募集していません
- Medicover Neuroendokrinologie MVZ
-
Münster、ドイツ、48149
- まだ募集していません
- Universitätsklinikum Münster
-
Würzburg、ドイツ、97080
- 募集
- Universitätsklinikum Würzburg
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study will enroll patients with acromegaly who are considered for treatment with octreotide subcutaneous depot and patients with acromegaly who have already initiated octreotide subcutaneous depot treatment. The study will be conducted in Germany, the UK, and the US.
説明
Inclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for acromegaly
Exclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly
- Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
時間枠:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
時間枠:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with IGF-1 ≤1×ULN over time.
時間枠:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in GH levels over time.
時間枠:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with GH levels <1.0 μg/L over time.
時間枠:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
時間枠:From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
時間枠:From enrollment to the end of treatment at 2 years
|
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
時間枠:From enrollment to the end of treatment at 2 years
|
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
時間枠:From enrollment to the end of treatment at 2 years
|
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
時間枠:From enrollment to the end of treatment at 2 years
|
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。